Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear ...
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated ...
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy ...
Biopharma is rarely short on scientific promise. But in 2026, the questions facing the industry are increasingly practical: How can complex therapies be developed, manufactured, funded, and ...
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made ...
An integrated framework combining text mining and knowledge graph modeling supports biopharmaceutical process optimization. This content is an AI-generated, fully rewritten summary based on a ...
New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration AstraZeneca is the first major global biopharma to establish ...
Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year To seek approval for Arexvy, a vaccine for the prevention of lower ...
New leader will be based at the company’s new global headquarters in Singapore We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and ...
WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas. This content is an ...
Discover how the right excipient can support efficient processing, reliable dosing, fast dissolution and a more patient-friendly experience, and learn what galenIQ™ brings to modern sachet development ...
Outlook Therapeutics has won its appeal through the FDA’s Formal Dispute Resolution process for ONS-5010/LYTENAVA, an investigational ophthalmic formulation of bevacizumab-vikg for neovascular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results